(I)

CLAIM AMENDMENTS

1. (original) A method for reducing the consumption of fat-containing food and snacking, said method comprising administering to a subject in need thereof an effective amount of a compound of the general formula (I)

$$A = \begin{pmatrix} R^1 & R^4 & R^2 \\ R^4 & R^2 & R^3 \\ R^3 & R^3 \end{pmatrix}$$

wherein

B represents >NR³ or >CR⁵R⁶, wherein R³ and R⁶ independently are hydrogen; hydroxy; $C_{1.6}$ -alkoxy; or $C_{1.6}$ -alkyl, $C_{3.6}$ -cycloalkyl, $C_{2.6}$ -alkenyl or $C_{2.6}$ -alkynyl optionally mono- or polysubstituted with halogen; or R⁵ and R⁴ together represent one of the bonds in a double bond between the atoms 2 and 3 of formula (I);

D represents $-S(=O)_2$ - or -S(=O)-; or

D-B represents $-S(=O)(R^7)=N$ -

wherein R^7 is $C_{1.6}$ -alkyl; or aryl or heteroaryl optionally mono- or polysubstituted with halogen, hydroxy, $C_{1.6}$ -alkoxy, aryloxy, arylalkoxy, nitro, amino, $C_{1.6}$ -monoalkyl- or dialkylamino, cyano, acyl, or $C_{1.6}$ -alkoxycarbonyl;

 R^1 is hydrogen; hydroxy; $C_{1.6}$ -alkoxy; or $C_{1.6}$ -alkyl, $C_{3.6}$ -cycloalkyl, $C_{2.6}$ - alkenyl or $C_{2.6}$ - alkynyl optionally mono- or poly substituted with halogen and R^4 is hydrogen; or R^4 together with R^3 represent one of the bonds in a double bond between the atoms 2 and 3 of formula (I); or R^1 together with R^4 represent one of the bonds in a double bond between the atoms 3 and 4 of formula (I);

 R^2 is hydrogen; hydroxy; $C_{1.6}$ -alkoxy; or $C_{1.6}$ -alkyl, $C_{3.6}$ -cycloalkyl, $C_{2.6}$ - alkenyl or $C_{2.6}$ -alkynyl optionally mono- or poly substituted with halogen;

 R^3 is R^6 ; $-C(=X)R^6$; $-NR^8R^9$; bicycloalkyl, aryl, heteroaryl, arylalkyl or heteroarylalkyl optionally mono- or poly substituted with halogen, hydroxy, C_{1-6} -alkoxy, aryloxy, arylalkoxy, nitro, amino, C_{1-6} -monoalkyl- or dialkylamino, cyano, oxo, acyl or C_{1-6} -alkoxycarbonyl; or aryl substituted with C_{1-6} -alkyl;

wherein R^8 is hydrogen; C_{3-6} -cycloalkyl or $(C_{3-6}$ -cycl alkyl) C_{1-6} -alkyl, the C_{3-6} -cycloalkyl group optionally being mono- or poly substituted with C_{1-6} -alkyl, halogen, hydroxy or C_{1-6} -alkoxy; a 3-6 membered saturated ring system comprising one or more nitrogen-, oxygen- or sulfur atoms; or straight or branched C_{1-18} -alkyl optionally mono- or poly substituted with halogen, hydroxy, C_{1-6} -alkoxy, C_{1-6} -alkylthio, C_{3-6} -cycloalkyl, aryl, aryloxy, arylalkoxy, nitro, amino, C_{1-6} - monoalkyl- or dialkylamino, cyano, oxo, formyl, acyl, carboxy, C_{1-6} -alkoxy-carbonyl, or carbamoyl;

X is O or S;

R⁹ is hydrogen; $C_{1.6}$ -alkyl; $C_{2.6}$ -alkenyl; $C_{3.6}$ -cycloalkyl optionally mono- or polysubstituted with $C_{1.6}$ -alkyl, halogen, hydroxy or $C_{1.6}$ -alkoxy; or

R⁸ and R⁹ together with the nitrogen atom form a 3-12 membered mono- or bicyclic system, in which one or more of the carbon atoms may be exchanged with nitrogen, oxygen or sulfur, each of these ring systems optionally being mono- or poly substituted with halogen, C_{1.6}-alkyl, hydroxy, C_{1.6}-alkoxy, C_{1.6}-alkoxy-C_{1.6}-alkyl, nitro, amino, cyano, trifluoromethyl, C_{1.6}-monoalkyl- or dialkylamino, oxo; or

R3 is

wherein n. m, p independently are 0,1,2,3 and R¹⁰ is hydrogen; hydroxy; C_{1-6} -alkoxy; C_{3-6} -cycloalkyl optionally mono- or poly substituted with C_{1-6} -alkyl, halogen, hydroxy or C_{1-6} -alkoxy; C_{1-6} -alkenyl or C_{2-6} -alkynyl optionally mono- or polysubstituted with halogen; or

R² and R³ together with the nitrogen atom forms a 3-12 membered mono- or bicyclic system, in which one or more of the carbon atoms may be exchanged with nitrogen, oxygen or sulfur, each of these ring systems optionally being mono- or poly substituted with halogen, C_{1.6}-alkyl, hydroxy, C_{1.6}-alkoxy, C_{1.6}-alkoxy-C_{1.6}-alkyl, nitro, amino, cyano, trifluoromethyl, C_{1.6}-monoalkyl- r dialkylamino or oxo;

A together with carbon atoms 5 and 6 of formula (I) represents a 5 r 6 membered heterocyclic system comprising one or more nitrogen-, oxygen- or sulfur atoms, the heterocyclic systems optionally being mono- or poly substituted with halogen; C_{1,12}-alkyl; C_{1,6}-cycloalkyl; hydroxy; C₁₋₆-alkoxy; C₁₋₆-alkoxy-C₁₋₆-alkyl; nitro; amino; cyano; cyanomethyl; perhalomethyl; C_{1.6}-monoalkyl- or dialkylamino; sulfamoyl; C_{1.6}-alkylthio; C_{1.6}-alkylsulfonyl; $C_{1,6}$ -alkylsulfinyl: $C_{1,6}$ -alkylcarbonylamino; arylthio, arylsulfinyl, arylsulfonyl, the aryl group optionally being mono- or polysubstituted with C_{1.6}-alkyl, halogen, hydroxy or C_{1.6}-alkoxy; $C_{1.6}$ -alkoxycarbonyl; $C_{1.6}$ -alkoxycarbonyl- $C_{1.6}$ -alkyl; carbamyl; carbamyl- methyl; $C_{1.6}$ monoalkyl- or dialkylaminocarbonyl; C_{1.6}-monoalkyl- or dialkylaminothiocarbonyl; ureido; C₁₋₆-monoalkyl- or dialkylaminocarbonylamino, thioureido; C₁₋₆-monoalkyl- or dialkylaminothiocarbonyl- amino; $C_{1.6}$ -monoalkyl- or dialkylaminosulfonyl; carboxy; carboxy-C1.6-alkyl; acyl; aryl, arylalkyl, aryloxy, the aryl group optionally being mono- or polysubstituted with C_{1.6}-alkyl, halogen, hydroxy or C_{1.6}-alkoxy; (1,2,4-oxadiazol-5-yl)- or (1,2,4-oxadiazol-3-yl)-C_{1.6}-alkyl the oxadiazolyl group optionally being substituted with C_{1.6}alkyl or C_{3.6}-cycloalkyl; or a 5 - 6 membered nitrogen containing ring, optionally substituted with phenyl or C1.6-alkyl; or

a salt thereof with a pharmaceutically acceptable acid or base including all optical isomers of compounds of formula (I), some of which are optically active, and also their mixtures including racemic mixtures, or any tautomeric form thereof.

- (previously amended) The method according to claim 1, wherein the fat-containing food contains at least about 10 kcal% fat.
- 3. (original) The method according to claim 1 wherein the fat-containing food contains at least about 15 kcal% fat.
- 4. (original) The method according to claim 1 wherein the fat-containing food contains at least about 30 kcal% fat.
- 5. (original) The method according to claim 1 wherein the fat-containing food contains at least about 45 kcal% fat.
- 6. (original) The method according to claim 1 wherein the food consumption is related to snacking.



- 7. (original) The method according to claim 1, wherein B is >NR⁵ and R⁵ and R⁴ together represent one of the bonds in a double bond between the atoms 2 and 3 of formula (I).
- 8. (original) The method according to claim 1, wherein D is $-S(=O)_2$.
- 9. (original) The method according to claim 1, wherein R² is hydrogen or C_{1.6}-alkyl.
- 10. (original) The method according to claim 1, wherein R^3 is R^8 , $-OR^8$, NR^6R^9 or aryl, the aryl groups optionally being substituted with C_{1-6} -alkyl; wherein

 R^8 is hydrogen; $C_{3.6}$ -cycloalkyl; $(C_{3.6}$ -cycloalkyl) $C_{1.6}$ -alkyl; a 3 - 6 membered saturated ring system comprising one, two or three nitrogen-, oxygen- or sulfur atoms; or straight or branched $C_{1.18}$ -alkyl optionally substituted with halogen, hydroxy, $C_{1.6}$ -alkoxy, $C_{1.6}$ -alkylthio, $C_{3.6}$ -cycloalkyl or aryl,

R⁹ is hydrogen, C_{1.6}-alkyl or C_{3.6}-cycloalkyl; or

R⁴ and R⁹ together with the nitrogen atom form a 4 - 6 membered ring.

- 11. (original) The method according to claim 1, wherein \mathbb{R}^3 is secondary $\mathbb{C}_{3.6}$ -alkyl, tertiary $\mathbb{C}_{4.6}$ -alkyl, $\mathbb{C}_{3.6}$ -cycloalkyl or ($\mathbb{C}_{3.6}$ -cycloalkyl)methyl.
- 12. (original) The method according to claim 1, wherein A together with carbon atoms 5 and 6 of formula (I) forms a 5 membered heterocyclic system containing one hetero atom selected from nitrogen and sulfur, the heterocyclic system optionally being mono- or disubstituted with halogen; $C_{1\cdot12}$ -alkyl; $C_{3\cdot6}$ -cycloalkyl; cyano; cyanomethyl; perhalomethyl; sulfamoyl; $C_{1\cdot6}$ -alkylsulfonyl; $C_{1\cdot6}$ -alkylsulfinyl; arylthio, arylsulfinyl, arylsulfonyl, the aryl group optionally being mono- or polysubstituted with $C_{1\cdot6}$ -alkyl, halogen, hydroxy or $C_{1\cdot6}$ -alkoxy; $C_{1\cdot6}$ -alkoxycarbonyl- $C_{1\cdot6}$ -alkyl; carbamylmethyl; carboxy- $C_{1\cdot6}$ -alkyl; aryloxy; (1,2,4-oxadiazol-5-yl)- or (1,2,4-oxadiazol-3-yl) $C_{1\cdot6}$ -alkyl, the oxadiazolyl group optionally being substituted with $C_{1\cdot6}$ -alkyl or $C_{3\cdot6}$ -cycloalkyl; acyl or a 5 6 membered nitrogen containing ring, optionally substituted with phenyl or $C_{1\cdot6}$ -alkyl.

Claims 13-18 are cancelled.

19. (original) The method according to claim 1, wherein the general formula (I) is



wherein

X and Y independently are hydrogen, halogen, perhalomethyl, C₁₋₆-alkyl or C₁₋₆-alkoxy;

 R^{11} . R^{21} and R^{31} independently are $C_{1.6}$ -alkyl, $C_{2.6}$ -alkenyl, $C_{3.6}$ -alkynyl, $C_{3.6}$ -cycloalkyl, carboxy, $C_{1.6}$ -alkoxycarbonyl or aryl, all of which are optionally being mono- or polysubstituted with halogen, hydroxy, oxo, or aryl; or

 R^{11} is as defined above and R^{21} -C- R^{31} form a $C_{3.6}$ -cycloalkyl group, optionally being mono- or polysubstituted with $C_{1.6}$ -alkyl, perhalomethyl, halogen, hydroxy or aryl; or

-CR¹¹R²¹R³¹ form a 4- to 12-membered bicyclic or tricyclic carbocyclic system, optionally being mono- or polysubstituted with C_{1.6}-alkyl, perhalomethyl, halogen, hydroxy or aryl; or

a salt thereof with a pharmaceutically acceptable acid or base including all optical isomers of compounds of formula (Ia), some of which are optically active, and also their mixtures including racemic mixtures, or any tautomeric form thereof.

- 20. (original) The method according to claim 19, wherein X is halogen and Y is hydrogen.
- 21. (original) The method according to claim 20, wherein X is chloro.
- 22. (original) The method according to claim 19, wherein R11, R21 and R31 all are C1.6-alkyl.
- 23. (original) The method according to claim 19, wherein R¹¹ is methyl.
- 24. (original) The method according to claim 19, wherein R²¹-C-R³¹ forms a C₃₋₆-cycloalkyl group.

Claim 25 is cancelled.

26. (original) The method according to claim 19, wherein the compound of formula (Ia) is 3-tert-Butylamino-6-chloro-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide; 6-Chloro-3-(1,1-dimethylpropylamino)-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide; 6-Chloro-3-(1-methylcyclopropyl)amino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide;

6-Chloro-3-(2-hydroxy-1,1-dimethylethylamino)-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide;

6-Chloro-3-(1,1,3,3-tetramethylbutylamino)-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide;

3-(1-Adamantyl)amino-6-chloro-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide;

 $1-(6-Chloro-1,4-dihydro-1,1-dioxo-thieno[3,2-e]-1\lambda^6,2,4-thiadiazin-3-ylamino)-1-(6-Chloro-1,4-dihydro-1,1-dioxo-thieno[3,2-e]-1\lambda^6,2,4-thiadiazin-3-ylamino)-1-(6-Chloro-1,4-dihydro-1,1-dioxo-thieno[3,2-e]-1\lambda^6,2,4-thiadiazin-3-ylamino)-1-(6-Chloro-1,4-dihydro-1,1-dioxo-thieno[3,2-e]-1\lambda^6,2,4-thiadiazin-3-ylamino)-1-(6-Chloro-1,4-dihydro-1,1-dioxo-thieno[3,2-e]-1\lambda^6,2,4-thiadiazin-3-ylamino)-1-(6-Chloro-1,4-dihydro-1,4-dioxo-thieno[3,2-e]-1\lambda^6,2,4-thiadiazin-3-ylamino)-1-(6-Chloro-1,4-dihydro-1,4-dioxo-thieno[3,2-e]-1\lambda^6,2,4-thiadiazin-3-ylamino)-1-(6-Chloro-1,4-dihydro-1,4-dioxo-thieno[3,2-e]-1\lambda^6,2,4-thiadiazin-3-ylamino)-1-(6-Chloro-1,4-dioxo-thieno[3,2-e]-1\lambda^6,2,4-thiadiazin-3-ylamino)-1-(6-Chloro-1,4-dioxo-thieno[3,2-e]-1\lambda^6,2,4-thiadiazin-3-ylamino)-1-(6-Chloro-1,4-dioxo-thieno[3,2-e]-1-(6-Chloro-1,4-di$

cyclopropanecarboxylic acid ethyl ester;

6-Chloro-3-(1-methyl-1-phenylethyl)amino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide;

6-Chloro-3-(1-hydroxymethylcyclopentyl)amino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide;

1-(6-Chloro-1,4-dihydro-1,1-dioxo-thieno[3,2-e]-1λ⁶,2,4-thiadiazin-3-ylamino)-cyclopropanecarboxylic acid;

6-Chloro-3-(1-methylcyclobutyl)amino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide;

6-Chloro-3-(1-methylcyclohexyl)amino-4H-thicno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide;

6-Chloro-3-(1-methylcyclopentyl)amino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide;

6-Chloro-3-(1-ethylcyclobutyl)amino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide; or

a salt thereof with a pharmaceutically acceptable acid or base including all optical isomers of compounds of formula (Ia), some of which are optically active, and also their mixtures including racemic mixtures, or any tautomeric form thereof.

27. (original) The method according to claim 19, wherein the compound of formula (Ia) is 6-Chloro-3-(1-methylcyclopropyl)amino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide, or a salt thereof with a pharmaceutically acceptable acid or base including all optical isomers of compounds of formula (Ia), some of which are optically active, and also their mixtures including racemic mixtures, or any tautomeric form thereof.

Claims 28-43 are cancelled.

